José-Alain Sahel
Président chez Vision Institute
Profil
José-Alain Sahel is the founder of Gensight Biologics SA (founded in 2012) and Pixium Vision SA (founded in 2011).
Dr. Sahel is also the founder of SparingVision SAS, Fovea Pharmaceuticals SA, and Institut de la Vision.
Dr. Sahel's current job(s) include being the Chairman of the Ophthalmology Department at Fondation Ophtalmologique Adolphe de Rothschild, Chairman of the Vision Institute, Director of the Retinal Degeneration Fund (starting in 2022), Professor at University College London, Member of Institut de France and Academia Ophthalmologica Internationalis, and Senior Advisor at UPMC Enterprises.
Dr. Sahel's former job includes being a Professor at Université Pierre et Marie Curie.
Postes actifs de José-Alain Sahel
| Sociétés | Poste | Début |
|---|---|---|
| University College London | Corporate Officer/Principal | 05/10/2009 |
Fondation Ophtalmologique Adolphe de Rothschild
 Fondation Ophtalmologique Adolphe de Rothschild Hospital/Nursing ManagementHealth Services Fondation Ophtalmologique Adolphe de Rothschild is a specialized hospital in Paris, FR that focuses on treating all pathologies related to the head and neck for both adults and children. The hospital has a pharmacy that ensures the supply of medicines and medical devices. The hospital also has a clinical research service that serves as a one-stop-shop for investigators and industrial or academic partners. The hospital is supported by the Edmond de Rothschild Foundations, which offer a Medical Fellowship program to support talented and promising young practitioners in their hospital-university dynamic. The CEO of the French company is Julien Gottsmann. | Corporate Officer/Principal | - |
Institut de France
 Institut de France Miscellaneous Commercial ServicesCommercial Services Institut de France engages in the development of the arts and sciences. Its goal is to improve the arts and sciences in line with the principle of pluridisciplinarity and manage the thousands of donations, legacies, and foundations. The company was founded in 1795 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
| Academia Ophthalmologica Internationalis | Corporate Officer/Principal | - |
| Vision Institute | Président | - |
| Retinal Degeneration Fund | Directeur/Membre du Conseil | 21/07/2022 |
UPMC Enterprises
 UPMC Enterprises Investment ManagersFinance UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania. | Consultant / Advisor | - |
Anciens postes connus de José-Alain Sahel
| Sociétés | Poste | Fin |
|---|---|---|
SparingVision SAS
 SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Fondateur | - |
| GENSIGHT BIOLOGICS S.A. | Fondateur | - |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░ | - |
| ░░░░░░░░ ░░ ░░ ░░░░░░ | ░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░ | ░░░░░░░░░ | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PIXIUM VISION | Health Technology |
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
| Université Pierre et Marie Curie | Consumer Services |
Institut de France
Institut de France Miscellaneous Commercial ServicesCommercial Services Institut de France engages in the development of the arts and sciences. Its goal is to improve the arts and sciences in line with the principle of pluridisciplinarity and manage the thousands of donations, legacies, and foundations. The company was founded in 1795 and is headquartered in Paris, France. | Commercial Services |
Fondation Ophtalmologique Adolphe de Rothschild
Fondation Ophtalmologique Adolphe de Rothschild Hospital/Nursing ManagementHealth Services Fondation Ophtalmologique Adolphe de Rothschild is a specialized hospital in Paris, FR that focuses on treating all pathologies related to the head and neck for both adults and children. The hospital has a pharmacy that ensures the supply of medicines and medical devices. The hospital also has a clinical research service that serves as a one-stop-shop for investigators and industrial or academic partners. The hospital is supported by the Edmond de Rothschild Foundations, which offer a Medical Fellowship program to support talented and promising young practitioners in their hospital-university dynamic. The CEO of the French company is Julien Gottsmann. | Health Services |
Institut de la Vision
 Institut de la Vision Medical/Nursing ServicesHealth Services Institut de la Vision is a research center located in Paris, France that focuses on discovering, developing, and testing treatments and technological innovations for eye diseases. The French company's objective is to improve the autonomy and quality of life of patients. The private company was founded by José-Alain Sahel. | Health Services |
UPMC Enterprises
UPMC Enterprises Investment ManagersFinance UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania. | Finance |
SparingVision SAS
SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Health Technology |
| Retinal Degeneration Fund | |
| Vision Institute | |
| Academia Ophthalmologica Internationalis |
